Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

S. J. Schraa, K. L. van Rooijen, D. E. W. van der Kruijssen, C. Rubio Alarcon, J. Phallen, M. Sausen, J. Simmons, V. M. H. Coupe, W. M. U. van Grevenstein, S. Elias, H. M. Verkooijen, M. M. Lacle, L. J. W. Bosch, D. van den Broek, G. A. Meijer, V. E. Velculescu, R. J. A. Fijneman, G. R. Vink, M. Koopman*, Liselot van IerselPLCRC-MEDOCC group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number790
Number of pages10
JournalBMC Cancer
Volume20
Issue number1
DOIs
Publication statusPublished - 20 Aug 2020

Keywords

  • Colon cancer
  • Circulating tumor DNA
  • ctDNA
  • Adjuvant chemotherapy
  • TwiCs
  • RANDOMIZED CONTROLLED-TRIAL
  • CELL-FREE DNA
  • COLORECTAL-CANCER
  • RESIDUAL DISEASE
  • FLUOROURACIL
  • RECURRENCE
  • SURVIVAL
  • LEUCOVORIN
  • RISK
  • OXALIPLATIN

Cite this